Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
Hallador Energy
HNRG
$670M
| $337K | ﹤0.01% |
63,307
| – | – |
|
3152
USCB Financial Holdings
USCB
$406M
| $336K | ﹤0.01% |
29,478
| – | – |
|
3153
Cadiz
CDZI
$251M
| $335K | ﹤0.01% |
115,582
| – | – |
|
|
LICY
3154
DELISTED
Li-Cycle Holdings Corp.
LICY
| $328K | ﹤0.01% |
39,804
| – | – |
|
3155
Red Robin
RRGB
$145M
| $328K | ﹤0.01% |
42,799
| – | – |
|
3156
Verrica Pharmaceuticals
VRCA
$89.7M
| $328K | ﹤0.01% |
5,536
| – | – |
|
3157
Torrid Holdings
CURV
$254M
| $326K | ﹤0.01% |
66,890
+8,175
| +14% | +$40.3K |
|
3158
HF Foods Group
HFFG
$80.2M
| $324K | ﹤0.01% |
92,601
-16,494
| -15% | -$72.2K |
|
3159
Douglas Elliman
DOUG
$154M
| $323K | ﹤0.01% |
204,399
-1,400,682
| -87% | -$2.87M |
|
3160
System1
SST
$14.3M
| $323K | ﹤0.01% |
16,472
-4,453
| -21% | -$75.9K |
|
|
GAMB
3161
DELISTED
Gambling.com
GAMB
| $322K | ﹤0.01% |
35,321
| – | – |
|
3162
LiveWire
LVWR
$371M
| $322K | ﹤0.01% |
44,591
| – | – |
|
3163
Citius Pharmaceuticals
CTXR
$15.6M
| $320K | ﹤0.01% |
14,280
| – | – |
|
|
MURA
3164
DELISTED
Mural Oncology
MURA
| $318K | ﹤0.01% |
65,082
-16,126
| -20% | -$78.3K |
|
3165
Metagenomi Therapeutics
MGX
$44.8M
| $318K | ﹤0.01% |
+30,148
| New | +$347K |
|
3166
Veritone
VERI
$101M
| $315K | ﹤0.01% |
59,872
| – | – |
|
3167
Talkspace
TALK
$874M
| $315K | ﹤0.01% |
88,164
| – | – |
|
|
GPGI
3168
GPGI Inc
GPGI
$3.83B
| $310K | ﹤0.01% |
51,606
| – | – |
|
3169
Paysign
PAYS
$501M
| $308K | ﹤0.01% |
84,171
| – | – |
|
|
SLNO
3170
DELISTED
Soleno Therapeutics
SLNO
| $308K | ﹤0.01% |
7,195
| – | – |
|
3171
PDS Biotechnology
PDSB
$38.4M
| $306K | ﹤0.01% |
77,203
| – | – |
|
3172
First Western Financial
MYFW
$304M
| $306K | ﹤0.01% |
20,962
| – | – |
|
3173
Southland Holdings
SLND
$30.2M
| $304K | ﹤0.01% |
58,983
+1,410
| +2% | +$6.99K |
|
3174
Richardson Electronics
RELL
$267M
| $303K | ﹤0.01% |
32,913
| – | – |
|
3175
Standard BioTools
LAB
$340M
| $302K | ﹤0.01% |
111,584
+80,392
| +258% | +$194K |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.